Enabling happier and healthier lives.
Our vision
Humankind is still suffering from diseases that are considered incurable.
We design and discover medicines for these incurable diseases through event-driven pharmacology by exploiting AI to design proximity-inducing compounds (PICs™).
We envision a society where patients and physicians have precise control of pathogenic human protein concentrations via small molecules.

Our mission
Our mission is to bring multiple first-in-class small molecule PICs™ to market as drugs against hard-to-drug targets by 2035.
PICs™ induce proximity to cellular degradation machinery and require a deep understanding of chemistry and biology to be successfully developed. PICs™ are optimized for their physicochemical properties and offer distinct advantages for therapeutic development, such as oral bioavailability and permeability.
We developed our CelerisTx One™ platform to design such drugs and to rationally improve them in a closed-loop.
Our platform is a holistic solution to design the components necessary to induce protein proximity. CelerisTx One™ automates subsequent chemical and biological tasks before proceeding through multiple design-make-test iterations to develop medicines for high unmet medical needs.
Driven by people.
Team



DI Christopher Trummer
CEO, Co-Founder and President
Jakob Hohenberger
CFO/COO, Co-Founder and Director
Dr. Chris Tame
VP, Head of Drug Discovery

Christopher Trummer
CEO and Co-Founder

Jakob Hohenberger
CFO/COO and Co-Founder

Dr. Chris Tame
VP, Head of Drug Discovery

Alexandra Moik

Dr. Arjun Rao

Dr. Oskar Hoff

Dr. Michael Brunsteiner

Dr. Honorine Lebraud

Dr. Krisztián Gál

Tatjana Hirschmugl, MSc.

Dr. Sagar Gore

Dr. Sridhar Radhakrishnan

Tin Tunjic

Dr. Alzbeta Tuerkova

Christina Hetzmannseder

Dr. Federica Ponti

Leonie Reichmann

Dr. Adam Yip

Dr. Andrew Potterton

Dr. Rosa Cookson
Board of Directors



Dr. Peter Ho
Board Director
Karel Kubias
Board Director
Dr. James Field
Board Director

Dr. James Field
Board Director

Karel Kubias
Board Director

Dr. Peter Ho
Board Director
Scientific Advisory Board

Assoc.-Prof. Dr. Johannes Kirchmair
University of Vienna
Computational Drug Discovery & Design Group

Prof. Dr. Ola Spjuth
University of Uppsala
Pharmaceutical Biosciences and Bioinformatics

Prof. Dr. Jean-Louis Reymond
University of Bern
Chemistry and Drug Design

Prof. Dr. Stefan Knapp
Goethe University Frankfurt
Pharmaceutical Chemistry

Dr. Mark Whittaker
Former SVP Head of Protein Homeostasis at Evotec